---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-193412"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:12:14.690720+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Q2 net loss $462.5M on $425.1M AnHeart charge; halts NUV-868 Phase 2

## Summary
- Net loss of $462.5M ($1.89/share) vs. $20.6M ($0.09) Q2 2023; includes $425.1M acquired IPR&D charge from AnHeart acquisition.
- Cash, equivalents, and marketable securities of $577.2M as of June 30, 2024.
- R&D expenses $29.2M (up 57% YoY) and G&A $16.1M (up 115% YoY) partly due to AnHeart.
- Decided not to initiate Phase 2 for NUV-868 in prior solid tumor indications; evaluating next steps.
- Taletrectinib NDA planned in U.S. in 2025 based on pooled TRUST-I/II data at ESMO 2024; received FDA Orphan Drug Designation.

## SEC filing metadata
- accession: 0001193125-24-193412
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312524193412/0001193125-24-193412-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312524193412/d867853d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-193412
- JSON: https://secwatch.observer/filing/0001193125-24-193412.json
- Plain text: https://secwatch.observer/filing/0001193125-24-193412.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.